Gut ist eine Lehrart, wo man vom Bekannten zum Unbekannten fortschreitet; schon ist sie, wenn sie sokratisch ist, d.i. wenn sie dieselben Wahrheiten aus dem Kopf und Herzen des Zuhorers herausfragt. Bei der ersten werden dem Verstand seine Uberzeugungen in Form abgefordert, bei der zweiten sie ihm abgelockt. Professor Friederich Schiller Jena, in a letter written on 23 February 1793 to his friend and supporter Korner, father of the poet Theodor Korner. Established clinicians and scientists as weil as students aga in tried the Wilsede experiment for three days and nights and learned from each other. In our fourth Wilsede meeting on "Modern Trends in Human Leukemia" we concentrated once again on questions re gar ding the practical application of research and its benefits to the patient. The main emphasis of leukemia research has changed since the first Wilsede meeting in 1973. Virology is no longer the sole interest. Advances in immunology and cell genetics and a better understanding of Dr. h. c. Alfred Toepfer speeking with participants of the meeting in Wilsede XXI Arrival and discussion of participants in front of the meeting pI ace "De Emmenhoff" XXII Personal and scientific discussion in Wilsede June 1980 Fotos: R. Vols XXIII the mechanisms regulating normal and pathological blood cell differen tiation have had a considerable impact on the direction of leukemia research."

Research on aplastic anaemia has until recently been limited to clinical description, morphology and epidemiology. New methods to culture haemopoietic cells, and advances in our knowledge of proliferation and differentiation in the haemopoietic cell system .opened a new area of scientific interest for this "prototype" of haemopoietic failure. In addition, bone marrow transplantation became not only a clinical method of treatment, but also a source of data useful for the discussion of pathophysiological models of aplastic anaemia. This situation prompted us to arrange an international con ference on aplastic anaemia, with particular emphasis on its patho physiology and the rationals of the current therapeutic approaches. This conference was held at Schloss Reisensburg from July 20-22, 1978 with the participation of both experimental and clinical scientists active in this field or in related areas of research. The proceedings of the symposion reflect the present knowledge as well as the many new questions which arose from the discussions. The editors are gratefully indebted to the participants of this meeting, to Gerlinde Trogele and all the co-workers of the Uni versity of Ulm engaged in preparation of this symposium and of this volume, and last not least to all sponsors who provided the financial basis for this scientific event."

The contact between the human blood and foreign technical apparatus (circulatory) and respiratory assist devices, arti ficial kidneys) leads to changes in the plasmatic and cel lular components of the blood, which have often only been taken as signs of gross but passive blood destruction. There is much evidence to support this notion in parts (mechanical cellolysis of erythrocytes and thrombocytes), however, these changes have to be seen in a broader bio logical context as an organ-specific reaction of the blood. It is an unjustified oversimplification to simply treat the blood as transport organ for respiratory gases (02 and CO ) and metabolites. The blood is rather also an organ 2 system for specific and unspecific defense mechanisms, di rected against the hazards of mechanical, microbiological and toxicological risks posed to multicellular macro-orga nisms in an environment in which trauma and other distur bances of the physical integrity are common. The two defense systems of the blood are based on humural and cellular constituents; the latter have to be considered as "excitable cells," capable of responding in a predictable and automatic fashion to adequate stimuli. The response of the cellular constituents in controlled and coordinated by chemical mediators. The immunological research of the last century has distinguished two separate defense systems of the blood: I. The highly specific defense system (immune system sen sustrictori) which is phylogenetically new and is ontogenetically learned."

Bone marrow transplantation, the goal which integrates hemato logists, immunologists, geneticists, oncologists and specialists of several other fields, has overcome its state of stagnation in recent years. Clinically as well as experimentally new approaches to old problems and new conclusions from recent findings proliferate: bone marrow transplantation in leukemic remission, bone marrow growth in cell culture, bone marrow manipulation with antisera, bone marrow differentiation in histoincompatible hosts, immuno suppression with partial body irradiation to cite just a few. These and other new developments were discussed by experts from 12 countries in and outside the European Community during an international seminar held on March 8-10, 1979 by the "Institut fur Hamatologie, GSF," under the auspices of the European Communities. The editors thank both the contributors to this symposium, who made it a successful meeting and submitted their manuscripts punctually, and the publishers, who have provided a volume of high quality in good time. They are also grateful for the valuable cooperation from numerous colleagues at the Institut fur Hamato logie."

In light of recent advances in scientific understanding, this textbook provides a comprehensive yet focused guide to anemia, the most common hematologic malady in medicine. This authoritative, clinical resource covers the scientific basis of the many forms of anemia, while offering a practical approach to prognosis, diagnosis and management. Chapters cover a multitude of topics, ranging from the basic components and physiologic functions, to secondary anemias and transfusion therapy. Modern in approach, this text also looks ahead to new and innovative methodologies. With recommended treatment plans and many case studies, this heavily-illustrated book is essential reading for hematologists and oncologists. In providing a pathophysiologic context, it is also of interest to nurse practitioners, physician assistants and medical students in the field. This book provides access to an online version on Cambridge Core, which can be accessed via the code printed on the inside of the cover.

Even though numerous questions with regard to the pathogenesis of athero sclerosis have not yet been answered, the accumulated evidence indicates significant regression of lesions in experimental animals. This is discussed extensively in this monograph, as are the mechanisms involved in regression of lesions. Whether human atherosclerosis has the potential for regression appears to be the most important, but at the same time the most difficult question to answer. Contrary to experimental atherosclerosis in animals, which can be produced and which can regress within a few months, human lesions in general develop slowly over many years. Therefore, measures aimed at modifying this process may also require many years to be successful. In addition, repeated direct examination of lesions in the human is usually not possible. Nevertheless, recent reports in patients with hyperlipoproteinemias indicate that pronounced and maintained control of hyperlipidemias may lead, even within months, to regression as evidenced by angiography or sophisticated measurements of peripheral circulation. The monograph is divided into two sections. The first will deal with of lipid deposition in the arterial wall, whether "atherogenesis" mechanisms or not there is evidence of monoclonal origin of human atherosclerosis plaques, cell culture and factors that stimulate smooth muscle proliferation, and animal models of atherogenesis. This section is concluded with a discussion of dietary factors other than lipids in atherogenesis."

clinical efficacy of haemostatic agents had to be published work and had to fulftl most of the following minimum requirements: (1) Quantitation ofthe measured blood loss was required, and not merely a clinical impression of the amount of blood lost, if the document pertained to a planned but "open" clinical trial. (2) Only double-blind trials with random allocation of the placebo and experimental drug to preselected patients were considered suitable for discussion, if the blood loss had not been quantitated in a prospective trial. (3) Defmition and appropriate selection of patients admitted to the trial: all inclusion and exclusion criteria used to select patients had to be mentioned in detail. (4) Once included in the trial, patients could be withdrawn only on the basis of strict criteria for withdrawal which had been defined in advance. (5) A double-blind trial had to be continued for an adequate length of time if the haemostatic agent was being assessed in the prevention of bleeding in patients with a long lasting bleeding disorder . (6) A clear and detailed statistical analysis of the results was required. Moreover, a clear distinction between the therapeutic and prophylactic value of the haemostatic agent had to be made and applied separately to the group of patients without any major basic disorder and those with a bleeding disorder e.g. : chronic thrombocytopenia, haemophilia, Rendu-Osler telangiectasia ... General statements not substantiated by experimental data, even when issued by well-known authorities, were not considered a reasonable basis for discussion.

It is perhaps not too much of an exaggeration to claim that experimental hematology as it flourishes today originated largely from the pioneering attempts to protect lethally radiated animals (I) by shielding of hemopoietic tissues by L. 0. Jacobson (9), and (2) by treatment with bone marrow suspensions by E. Lorenz and his col- laborators (12). The site chosen for this annual meeting of the International Society for Experi- mental Hematology is given a special historic sig- nificance by the fact that it was 25 years ago that the first publication on this subject by Lorenz ap- peared from his laboratory at the National Insti- tutes of Health. Lorenz's discovery marked the beginning of a period which lasted until 1956, during which the protection afforded by hemopoietic cell suspensions was confirmed by many. This soon led to an intensive scientific de- bate on the mechanism of this protective effect: was it due to a humoral factor produced and pro- vided by the bone marrow-as Lorenz The Appearance of postulated-or to transplantation and subsequent proliferation of hemop- etic cells? This question was defini- 1 the Multipotential tively answered in 1956 by evidence from three different laboratories (7, 15, 26), which demonstrated the origin of the cells Hemopoietic in the repopulated tissues using a variety of cellu- lar and immunologic markers. By the same token, these contributions marked the birth of radiation Stem Cell chimeras.

This two-and-a-half-day symposium has concentrated on main aspects of the rapidly expanding field ofleukocyte markers in hematology. While leukemias are already being 'phenotyped' routinely in clinical centers, continued research on the developmental sta ge of cells and cell membranes, expanding into a malignant clone, permits new snap shots on hemopoietic differentiation. Thus the discovery of leukemia-associated anti gens, which so far have not been found on subpopulations of normal cells, has greatly stimulated the discussion on 'differentiation antigens versus tumor antigens'. The proceedings reflect the considerable success which has been achieved very re cently in the classification of hemoblastomas. Consequently the number of leukemias which are unclassifiable by immunological methods have dwindled down to a small mi nority. New facts give rise to new questions. By including the main points of the discussions in the proceedings, we wanted to give the reader an opportunity to get an impression of the questions and conclusions raised and drawn by the participants on the basis of new - and frequently still unpublished - data. The editors thank both the contributors to this symposium, who made it a successful meeting and submitted their manuscripts punctually, and the publishers, who have provided a volume of high quality in good time. They are also grateful for the valuable cooperation from numerous colleages at the Institut fUr Hamatologie.

Jean BERNARD * I should like to begin with an assumption and a paradox. The assumption is that leukemia is a disease of a stem cell characterized by pathologie alterations of that cell and its progeny. All present research and discussions are centered around the leukemic cell. So is this symposium, which would not take place except for our primary interest in the leukemic cell. This does not preclude, of course, consideration of other definitions and other approaches to the prOblem. By definition, then, the leukemic cells are abnormal cells and their metabolism and functions are presumed to be abnormal. Yet, the classification of the different types of leukemias is based upon the characteristics of normal cells. We talk of "lymphoblasts" and "myeloblasts" as predominant cell types in leukemia. This leads to a double paradox. In the first pi ace it is clearly illogical to classify abnormal cells by their resemblance to normal cells, since their very abnormality consists in not being normal. Yet, as a second paradox, the classifica ti on has had the happy consequence of ai ding us in the treatment and prognosis of leukemia for the past 25 years. A more detailed analysis shows that the consequence of this paradox are complex: while there exists a useful correlation between cellular types, treatment and prognosis, numerous problems and difficulties persist. The most serious of them concems the "unclassified leukemias" which are the reason for this reunion.

The manifold problems of shock are still of great importance, diagnostic and therapeutic experience of the "severely ill" being supplied with new information almost every month. In the 5 periodicals which have found their way to my desk during the past few days there are no less than 10 interesting articles on questions concerning shock research [see Bibliography 41 b, 53 a, 60 a, 192 a, 242 a, 350 b, 810 a, 941 a, 1069 a, 1082 a]. The most urgent point still is to maintain as complete as possible the objective catalog of the various shock manifestations found in man and in animals - yet at the same time to view interpretations of these phenomena in their relative and temporal "truth". Problems of shock research are not only interesting for their scientific value but also for their clinical implication. In particular, almost every practicing physician is facing problems of blood replacement very frequent ly. The effective or circulating blood volume remains an important theoret ical and therapeutic problem in the shock field. For years, U. F. GRUBER has pursued this question clinically and experimentally. This volume deals with the world literature in an exceptionally thorough manner. This book is made more than a compilation by including a long list of original work done with F. D. MOORE in Boston, in the Surgical Department in Chur, with 1. E. GELIN and S. E.

The manifold problems of shock are still of great importance, diagnostic and therapeutic experience of the "severely ill" being supplied with new information almost every month. In the 5 periodicals which have found their way to my desk during the past few days there are no less than 10 interesting articles on questions concerning shock research see Bibliography 41 b, 53 a, 60 a, 192 a, 242 a, 350 b, 810 a, 941 a, 1069 a, 1082 a]. The most urgent point still is to maintain as complete as possible the objective catalog of the various shock manifestations found in man and in animals - yet at the same time to view interpretations of these phenomena in their relative and temporal "truth." Problems of shock research are not only interesting for their scientific value but also for their clinical implication. In particular, almost every practicing physician is facing problems of blood replacement very frequent ly. The effective or circulating blood volume remains an important theoret ical and therapeutic problem in the shock field. For years, U. F. GRUBER has pursued this question clinically and experimentally. This volume deals with the world literature in an exceptionally thorough manner. This book is made more than a compilation by including a long list of original work done with F. D. MOORE in Boston, in the Surgical Department in Chur, with L. E. GELIN and S. E."

Defined as red blood cell break down and the release of hemoglobin and intracellular contents into the plasma, haemolysis can seriously impact patient care as well as the laboratory's reputation through its affect on test results. Therefore, the European Preanalytical Scientific Committee, in collaboration with the International Federation of Clinical Chemistry Working Group on Patient Safety, have designed a questionnaire to collect data on prevalence and management of haemolytic specimens referred to the clinical laboratories for clinical chemistry testing. The new book will help identify the areas where haemolysis occurs most frequently, which can, in turn, guide further analysis about why it is occurring. Once these elements are known, practices and procedures can be implemented to dramatically reduce haemolysis and avoid erroneous laboratory results affecting patient care and increasing laboratory costs.

This publication collates the topics covered during the three workshops organized jointly by the Blood Services Group (BSG) of the Health Sciences Authority (HSA) in Singapore and the World Health Organization Regional Office for the Western Pacific (WPRO), Manila and Regional Office for South-East Asia (SEARO), New Delhi, supported by the Singapore Government through its Singapore Cooperation Programme. It will serve as a useful reference for public officers and professionals involved in the management of national blood services.Each workshop focused on key management areas that were deemed to be critical components of well-managed blood programs. Presentations on various aspects of these management areas, interspersed with practical sessions and group discussions, combined to provide participants an overview of key learning points. Round-table discussions and sharing of different practices gave a good understanding of management practices in the region and illustrated the many ways in which different issues and challenges could be managed.

This fully illustrated text is an essential guide for trainees in Haematology and Medicine studying for higher examinations, as well as for professionals wishing to expand their knowledge or revalidate. The book contains over 100 illustrated cases covering the whole field of malignant and non-malignant haematology, including coagulation problems and infectious diseases. Each case contains a set of questions written by two Royal College examiners, with answers on the reverse page. Readers can make differential diagnoses and devise treatment plans and prognoses, before turning the page to read the experts' detailed answers. The cases are presented in random order - just as they would be in real life - and are of varying lengths and degrees of difficulty, accompanied by hundreds of colour photomicrographs, photographs, and x-rays. This new edition is revised and updated, with new cases, images, and tables.

Platelets, Fourth Edition, integrates the entire field of platelet biology, pathophysiology, and clinical medicine with contributions from 142 world experts from 18 countries. This award-winning reference provides clear presentations by basic scientists on the cellular, molecular, and genetic mechanisms of platelets and the role of platelets in thrombosis, hemorrhage, inflammation, antimicrobial host defense, wound healing, angiogenesis and cancer. It also provides start-of-the-art presentations by hematologists, cardiologists, stroke physicians, blood bankers, pathologists and other clinicians on platelet function testing, disorders of platelet numbers and function, antiplatelet therapy and therapy to increase platelet numbers and/or function. Since the publication of the Third Edition of Platelets, there has been a rapid expansion of knowledge in both basic biology of platelets and the clinical approach to platelet-related diseases. This Fourth Edition of Platelets draws all this information into a single, comprehensive and authoritative resource.

The diagnosis and monitoring of hematological malignancies is complex and requires a systematic approach. Morphology, cell phenotyping, cytogenetics and molecular genetics are essential, and the results must be integrated. Diagnostic Techniques in Hematological Malignancies details the principles and applications of each of these test types in the diagnosis of hematological malignancies in blood and bone marrow. The first section describes the test modalities - including methodological principles, data interpretation and limitations - and is illustrated by clinical examples. The second section focuses on the clinical entities, detailing the most appropriate tests for diagnosis, staging and monitoring of different hematological malignancies and includes test utilization to identify prognostic markers and potential therapeutic targets. With contributions from multiple international experts, this illustrated book is an essential resource for qualified and trainee hematologists, oncologists, and pathologists. It's a practical and useful guide, providing a rational and structured approach to the laboratory assessment of hematological malignancies.

Following the familiar, easy-to-use at a Glance format, Haematology at a Glance, Fourth Edition is a broad and accessible introduction to the study of blood. Fully revised and updated to reflect advances in the field and in clinical practice, this new edition covers essential knowledge, from basic hematological physiology to blood disorders and their diagnosis and treatment. This new edition of Haematology at a Glance: * Features expanded sections on the underlying mechanisms, diagnostic techniques and management of the malignant haematological diseases. Also incorporates recent advances in knowledge of thrombosis and the newer oral anticoagulants * Contains the very latest clinical treatments * Includes updated illustrations and clinical photographs to illustrate concepts and aid understanding * Features extensive online self-assessment at www.ataglanceseries.com/haematology This book is an invaluable resource for medical students and health professionals wanting to consolidate and expand their knowledge of haematology.

New insights into the molecular biology of childhood leukemias have stimulated numerous advances in diagnostic methods, strategies for risk assessment and the development of novel therapy for genetic subtypes of the diseases. Fully revised and updated, this new edition of Childhood Leukemias provides the most comprehensive, clinically-oriented and authoritative reference dedicated to these diseases. Beginning with an overview of history, cell biology, and pathology, subsequent chapters review approaches in the evaluation and management of specific leukemias, new therapeutic development and the unique pharmacodynamics and pharmacogenetics of individual patients. New chapters include epigenetics of leukemias, leukemias in patients with Down syndrome and leukemia in adolescents and young adults. The final section covers the complications associated with the disease or its treatment and supportive care during and after treatment. Authored by leading experts, this is a 'must-have' for any physician or investigator who deals with leukemias in childhood.

Advances in Blood Cell Labeling; D.A. Goodwin, et al. A New Direct Method of Cell Labeling in Whole Blood by Administration of 111-In Labeled Antisense Oligonucleotide Probe; M.K. Dewanjee, et al. Transchelation of 114mIn from Iga-DTPA to Abscess-Related Proteins; A.J. Carlson, et al. The Antibody Approach of Labeling Blood Cells; S.C. Srivastava. Quality Control of Radiolabeled White Cells; A.M. Peters. Granulocyte Cell Labeling with TcNNOET; A. Moisan, et al. Arteriosclerosis and Monocyte Adhesion In vivo; I. Virgolini, et al. Stabilization of Exametazime for Leukocyte Labeling; C. Solanki, et al. 99mTc Labeling of Interleukin2 for In vivo Targetin of Activated TLymphocytes; M. Chianelli, et al. Nitric Oxide and Prostaglandin I2 for Radiolabeling of Human Platelets; I. Neumann, et al. 111In Labeling of Human IgG Using a DTPASIgG Kit; M. Roca, et al. 46 additional articles. Index.

Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.

This book has been highly successful ever since it was first published in 1958. Emphasis throughout is placed on diagnosis and management, with particular stress on clinical problems as they confront the practitioner. The new fifth edition has been completely revised and updated to take account of important recent developments such as AIDS, lymphomas and leukaemias, and in order to contain the length, some sections of the book have been condensed. The "British Medical Journal said of the fourth edition, Although this book is clearly orientated to bedside problems, it never fails to explain the

The essential guide for understanding and treating women with inherited bleeding disorders, revised and updated Now in its second edition, Inherited Bleeding Disorders in Women includes the most recent developments and research in the field. This important guide offers the most current information available for the effective management of these complex and difficult to diagnose disorders. Treating women with inherited bleeding disorders can be challenging and requires close collaboration among practitioners in different specialties. This important guide is written by a team of international experts who offer advice and practical suggestions for treating women with inherited bleeding disorders. Inherited Bleeding Disorders in Women comprehensively covers obstetric and gynecological issues for carriers of hemophilia, women with von Willebrand disease, rare bleeding disorders and inherited platelet disorders. This important resource: Offers an updated guide for hematologists, obstetricans and gynecologists and other clinicians treating women with inherited bleeding disorders Includes information for treating both common and rare bleeding disorders Contains the most recent developments and advances in the field for the treatment and management of inherited bleeding disorders in women Presents information from noted experts in the field Offers a multidisciplinary approach to the topic Written for hematologists, obstetricians and gynecologists and other clinicians working with women, Inherited Bleeding Disorders in Women has been fully revised and updated and continues to serve as a trusted guide for the management and treatment of women with inherited bleeding disorders.

In this thoroughly revised and expanded third edition of the highly praised classic, The Principles of Clinical Cytogenetics, a panel of hands-on experts update their descriptions of the basic concepts and interpretations involved in chromosome analysis to include the many advances that have occurred in the field. Among the highlights are a full chapter devoted to advances in chromosome microarray, soon to become a standard of care in this field, as well as an update on chromosome nomenclature as reflected in ISCN 2009. Other features include an update on automation to reflect the current state of the art, an update on hematopoietic neoplasms to reflect the new WHO guidelines, and updates on all regulatory changes that have been implemented. Cutting edge and readily accessible, The Principles of Clinical Cytogenetics, Third Edition offers physicians who depend on the cytogenetics laboratory for the diagnosis of their patients, students in cytogenetics programs, graduate and medical students studying for board examinations, cytogenetics technologists, and cytogeneticists a clear understanding of what happens in the cytogenetics laboratory to facilitate accurate and timely diagnoses.